A review of CCR5 antibodies against HIV: current and future aspects

Pavan Kumar Prathipati, Subhra Mandal, Christopher J. Destache

Research output: Contribution to journalArticle

Abstract

HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide. There has been tremendous research and development in the diagnosis, prevention and treatment of HIV. Small molecules have been shown to reduce the virus to nondetectable level in human plasma, however, there are reservoirs of latent virus that reemerge if antiretroviral therapy is stopped. There is no vaccine to prevent or cure HIV. A significant amount of research has been reported in the literature regarding antibodies for CCR5, a HIV entry host receptor. This report describes the role of CCR5 antibody in HIV prevention/treatment and how antibody-conjugated nanoparticles could be a future strategy with the potential to effectively eradicate the virus from the human system.

Original languageEnglish (US)
Pages (from-to)107-112
Number of pages6
JournalTherapeutic Delivery
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

HIV Antibodies
HIV
Viruses
Antibodies
Virus Diseases
Research
Nanoparticles
Vaccines

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

A review of CCR5 antibodies against HIV : current and future aspects. / Prathipati, Pavan Kumar; Mandal, Subhra; Destache, Christopher J.

In: Therapeutic Delivery, Vol. 10, No. 2, 01.02.2019, p. 107-112.

Research output: Contribution to journalArticle

Prathipati, Pavan Kumar ; Mandal, Subhra ; Destache, Christopher J. / A review of CCR5 antibodies against HIV : current and future aspects. In: Therapeutic Delivery. 2019 ; Vol. 10, No. 2. pp. 107-112.
@article{60c101c445364d9390b5991d94672728,
title = "A review of CCR5 antibodies against HIV: current and future aspects",
abstract = "HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide. There has been tremendous research and development in the diagnosis, prevention and treatment of HIV. Small molecules have been shown to reduce the virus to nondetectable level in human plasma, however, there are reservoirs of latent virus that reemerge if antiretroviral therapy is stopped. There is no vaccine to prevent or cure HIV. A significant amount of research has been reported in the literature regarding antibodies for CCR5, a HIV entry host receptor. This report describes the role of CCR5 antibody in HIV prevention/treatment and how antibody-conjugated nanoparticles could be a future strategy with the potential to effectively eradicate the virus from the human system.",
author = "Prathipati, {Pavan Kumar} and Subhra Mandal and Destache, {Christopher J.}",
year = "2019",
month = "2",
day = "1",
doi = "10.4155/tde-2018-0072",
language = "English (US)",
volume = "10",
pages = "107--112",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "2",

}

TY - JOUR

T1 - A review of CCR5 antibodies against HIV

T2 - current and future aspects

AU - Prathipati, Pavan Kumar

AU - Mandal, Subhra

AU - Destache, Christopher J.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide. There has been tremendous research and development in the diagnosis, prevention and treatment of HIV. Small molecules have been shown to reduce the virus to nondetectable level in human plasma, however, there are reservoirs of latent virus that reemerge if antiretroviral therapy is stopped. There is no vaccine to prevent or cure HIV. A significant amount of research has been reported in the literature regarding antibodies for CCR5, a HIV entry host receptor. This report describes the role of CCR5 antibody in HIV prevention/treatment and how antibody-conjugated nanoparticles could be a future strategy with the potential to effectively eradicate the virus from the human system.

AB - HIV is one of the most devastating viral infections the world has ever encountered. Ever since HIV was first identified in the 1980s, it has claimed millions of lives worldwide. There has been tremendous research and development in the diagnosis, prevention and treatment of HIV. Small molecules have been shown to reduce the virus to nondetectable level in human plasma, however, there are reservoirs of latent virus that reemerge if antiretroviral therapy is stopped. There is no vaccine to prevent or cure HIV. A significant amount of research has been reported in the literature regarding antibodies for CCR5, a HIV entry host receptor. This report describes the role of CCR5 antibody in HIV prevention/treatment and how antibody-conjugated nanoparticles could be a future strategy with the potential to effectively eradicate the virus from the human system.

UR - http://www.scopus.com/inward/record.url?scp=85061153861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061153861&partnerID=8YFLogxK

U2 - 10.4155/tde-2018-0072

DO - 10.4155/tde-2018-0072

M3 - Article

C2 - 30729884

AN - SCOPUS:85061153861

VL - 10

SP - 107

EP - 112

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 2

ER -